The latest oncology news listed by date, covering all clinical focus areas, tumour types and more
ASH 2024: High response rate, manageable adverse effects seen with epcoritamab in pretreated R/R CLL
In early results from a non-randomised study, the biologic agent epcoritamab, which leverages patients’ immune…